As of Sep 30
| +1.15 / +2.66%|
The 14 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 43.87, with a high estimate of 54.03 and a low estimate of 37.52. The median estimate represents a -1.11% decrease from the last price of 44.36.
The current consensus among 14 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.